Stock DRREDDY DR. REDDY'S LABORATORIES LIMITED
Add to a list

Dr. Reddy's Laboratories Limited Share Price

Equities

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:55 17/04/2026 pm IST 		5-day change 1st Jan Change
1,235.40 INR +1.16% Intraday chart for Dr. Reddy's Laboratories Limited +0.28% -2.80%
17/04 Asian Equities Traded in the US as American Depositary Receipts Surge in Friday Trading; Up 5% for Week MT
16/04 Asian Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading MT

Valuation: Dr. Reddy's Laboratories Limited

Capitalization 1,02900Cr 1.11TCr 941.64Cr 866.41Cr 819.99Cr 1.52TCr 1.55TCr 10TCr 3.98TCr 50TCr 4.17TCr 4.08TCr 1,75700Cr P/E ratio 2026 *
20.3x
P/E ratio 2027 * 22.2x
Enterprise value 1LCr 1.08TCr 914.83Cr 841.74Cr 796.64Cr 1.48TCr 1.5TCr 9.86TCr 3.87TCr 48TCr 4.05TCr 3.97TCr 1,70700Cr EV / Sales 2026 *
2.91x
EV / Sales 2027 * 2.7x
Free-Float
70.34%
Yield 2026 *
0.63%
Yield 2027 * 0.62%
* Estimated data More valuation ratios

Chart: Dr. Reddy's Laboratories Limited

Dynamic Chart

Latest news: Dr. Reddy's Laboratories Limited

17/04 Asian Equities Traded in the US as American Depositary Receipts Surge in Friday Trading; Up 5% for Week MT
16/04 Asian Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading MT
16/04 Dr. Reddy's Laboratories Board to Consider Final Dividend for Fiscal 2026 MT
16/04 India's Hetero targets annual sales of 1.5 million semaglutide pens in global rollout RE
15/04 Asian Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading MT
15/04 Dr. Reddy's Russia Unit Receives Final Tax Penalty Decision From Russian Tax Authority MT
13/04 Asian Equities Traded in the US as American Depositary Receipts Begin Week Lower MT
10/04 Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 5.6% for Week MT
08/04 Dr. Reddy's Laboratories to Divest Entire Stake in Svaas Wellness for INR22 Million MT
07/04 Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading MT
07/04 Dr Reddy's entered into an agreement for sale of its entire shareholding in its unit Svaas Wellness RE
07/04 Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited for INR 22.3 million. CI
06/04 Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
More news

Last Transcript: Dr. Reddy's Laboratories Limited

Logo Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, Q3 2026 Earnings Call, Jan 21, 2026
21/01
More transcripts

Analysts' recommendations: Dr. Reddy's Laboratories Limited

23/01 YES Research Upgrades Dr. Reddy's Laboratories to Add from Reduce, Price Target is INR1,340 MT
23/01 Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,600 From INR1,580, Keeps at Buy MT
22/01 ICICI Securities Upgrades Dr. Reddy's Laboratories to Add from Hold, Price Target is INR1,300 MT
22/01 Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,040 from INR1,100, Keeps at Underperform MT
30/25/30 Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy MT
More recommendations

Press Releases: Dr. Reddy's Laboratories Limited

23/02 Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept AQ
20/02 Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept BU
19/02 Dr Reddy Laboratories : . Reddy’s forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India PU
06/02 Dr Reddy Laboratories : Landscape Analysis on Alternatives to Animal Testing for Drug Development in India PU
29/01 Dr Reddy Laboratories : Corporate Governance Report PU
More press releases

News in other languages: Dr. Reddy's Laboratories Limited

03/04 En Inde, "les mariages Mounjaro" font florès
23/03 India, farmaceutiche lanciano prodotti generici a base di semaglutide
04/12 Aurigene Oncology Limited gibt vielversprechende erste Daten aus den ersten beiden Kohorten der Phase-1-Studie zu AUR112 bekannt, einem oral verabreichten niedermolekularen Inhibitor von MALT1, bei wieder auftretenden oder hartnäckigen...
04/12 Aurigene Oncology Limited annonce des données initiales encourageantes provenant des deux premiers groupes de l'étude de phase 1 évaluant l'AUR112, un inhibiteur oral à petites molécules de MALT1, pour les lymphopathies malignes...
24/25/24 Bourse : Safran, Sanofi et Accor assurent, Intel séduit, Mersen tangue
More news

Quotes and Performance

1 day+1.16%
1 week+0.28%
Current month-1.53%
1 month-3.72%
3 months+5.09%
6 months-1.64%
Current year-2.80%
More quotes

Course Extremes

1 week 1,196.15
Extreme 1196.15
 1,241.95
1 month 1,167.3
Extreme 1167.3
 1,310
Current year 1,149
Extreme 1149
 1,336.3
1 year 1,121.2
Extreme 1121.2
 1,377.95
3 years 876.68
Extreme 876.68
 1,420.2
5 years 731
Extreme 731
 1,420.2
10 years 377.6
Extreme 377.6
 1,420.2
More quotes

Managers and Directors: Dr. Reddy's Laboratories Limited

Manager TitleAgeSince
Erez Israeli CEO
 Chief Executive Officer 59 01/07/2019
B. Phanimitra CTO
 Chief Tech/Sci/R&D Officer - 01/08/2023
K. Randhir Singh CMP
 Compliance Officer - 17/03/2022
Director TitleAgeSince
Satish Kallam Reddy CHM
 Chairman 58 13/05/2014
Gunupati Prasad CHM
 Chairman 65 02/04/2013
Leo Puri BRD
 Director/Board Member 65 25/10/2018
More insiders

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
DR. REDDY'S LABORATORIES LIMITED Stock Dr. Reddy's Laboratories Limited
+1.16%+0.28%+6.16%+27.31% 1.11TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+2.55%-1.32%+10.37%+148.97% 83TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.15%-1.79%+48.71%+41.35% 56TCr
ABBVIE INC. Stock AbbVie Inc.
-0.29%+0.21%+20.46%+29.28% 37TCr
ROCHE HOLDING AG Stock Roche Holding AG
+2.07%+1.39%+25.20%+15.13% 33TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+1.72%-0.74%+49.33%+27.86% 32TCr
NOVARTIS AG Stock Novartis AG
+1.19%-2.41%+31.10%+34.87% 29TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+3.13%-1.94%+52.65%+3.53% 29TCr
AMGEN INC. Stock Amgen Inc.
+1.69%+1.22%+28.13%+43.23% 19TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.24%+8.21%-38.18%-55.23% 18TCr
Average +1.43%+0.16%+23.39%+31.63% 33.79TCr
Weighted average by Cap. +1.47%-0.62%+26.81%+53.63%
See all sector performances

Financials

2026 *2027 *
Net sales 34TCr 371.38Cr 314.6Cr 289.46Cr 273.95Cr 507.72Cr 516.64Cr 3.39TCr 1.33TCr 17TCr 1.39TCr 1.36TCr 59TCr 36TCr 386.24Cr 327.19Cr 301.05Cr 284.92Cr 528.04Cr 537.31Cr 3.53TCr 1.38TCr 17TCr 1.45TCr 1.42TCr 61TCr
Net income 5.07TCr 55Cr 46Cr 43Cr 40Cr 75Cr 76Cr 500.46Cr 196.24Cr 2.46TCr 205.66Cr 201.38Cr 8.67TCr 4.65TCr 50Cr 43Cr 39Cr 37Cr 69Cr 70Cr 458.86Cr 179.92Cr 2.25TCr 188.56Cr 184.64Cr 7.95TCr
Net Debt -2.93TCr -32Cr -27Cr -25Cr -23Cr -43Cr -44Cr -288.92Cr -113.29Cr -1.42TCr -118.72Cr -116.25Cr -5TCr -6.21TCr -67Cr -57Cr -52Cr -49Cr -92Cr -93Cr -612.14Cr -240.02Cr -3.01TCr -251.55Cr -246.31Cr -11TCr
* Estimated data More financial data

Company Profile

Logo Dr. Reddy's Laboratories Limited
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Employees
27,811
Sector
Pharmaceuticals
Calendar
12/05 - Earnings release - Q4 2026
More about the company

Quotes

Date Price Change Volume
17/26/17 1,235.40 ₹ +1.16% 76,118
16/26/16 1,221.25 ₹ +0.24% 83,520
15/26/15 1,218.30 ₹ -1.37% 1,53,125
13/26/13 1,235.20 ₹ +0.26% 33,085
10/26/10 1,232.00 ₹ +1.62% 87,690

Delayed Quote Bombay S.E.

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

BBB
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
38
Last Close Price
1,235.40INR
Average target price
1,318.45INR
Spread / Average Target
+6.72%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DRREDDY Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition